Telavancin: a novel lipoglycopeptide for serious gram-positive infections (Q36736356)

16 August 2017

1 reference

title

Telavancin: a novel lipoglycopeptide for serious gram-positive infections (English)

1 reference

16 August 2017

main subject

gram-positive bacteria

0 references

3

David P Nicolau

1 reference

16 August 2017

author name string

Somvadee Laohavaleeson

series ordinal

1

1 reference

16 August 2017

Joseph L Kuti

series ordinal

2

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 March 2007

1 reference

Expert Opinion on Investigational Drugs

16 August 2017

published in

1 reference

16 August 2017

volume

16

1 reference

16 August 2017

issue

3

1 reference

16 August 2017

page(s)

347-357

1 reference

Antimicrobial resistance in gram-positive bacteria

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.3.347

Defining the need for new antimicrobials: clinical and economic implications of resistance in the hospitalised patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.3.347

New antibiotics for the treatment of severe staphylococcal infection in the critically ill patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.3.347

Update on daptomycin: the first approved lipopeptide antibiotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.3.347

Methicillin-ResistantS. aureusInfections among Patients in the Emergency Department

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.3.347

Glycopeptides in clinical development: pharmacological profile and clinical perspectives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.3.347

The antimicrobial armamentarium: evaluating current and future treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.3.347

Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.3.347

Dimerization and membrane anchors in extracellular targeting of vancomycin group antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.3.347

Hydrophobic vancomycin derivatives with improved ADME properties: discovery of telavancin (TD-6424).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.3.347

Semi-synthetic glycopeptide antibacterials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.3.347

Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.3.347

Vancomycin analogues active against vanA-resistant strains inhibit bacterial transglycosylase without binding substrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.3.347

Glycopeptides: Update on an old successful antibiotic class

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.3.347

Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against Gram-positive bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.3.347

Telavancin: in vitro activity against staphylococci in a biofilm model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.3.347

In vitro activities of the new semisynthetic glycopeptide telavancin (TD-6424), vancomycin, daptomycin, linezolid, and four comparator agents against anaerobic gram-positive species and Corynebacterium spp

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.3.347

Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.3.347

Tissue penetration of telavancin after intravenous administration in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.3.347

In vitro activity of TD-6424 against Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.3.347

Evaluation of the extracellular and intracellular activities (human THP-1 macrophages) of telavancin versus vancomycin against methicillin-susceptible, methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.3.347

Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.3.347

Efficacy of Telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.3.347

Efficacy of telavancin (TD-6424), a rapidly bactericidal lipoglycopeptide with multiple mechanisms of action, in a murine model of pneumonia induced by methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.3.347

Efficacy of telavancin against penicillin-resistant pneumococci and Staphylococcus aureus in a rabbit meningitis model and determination of kinetic parameters

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.3.347

Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.3.347

Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.3.347

Effects of a new antibacterial, telavancin, on cardiac repolarization (QTc interval duration) in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.3.347

10.1517/13543784.16.3.347

21 January 2018

Identifiers

DOI

1 reference

16 August 2017

1 reference